Other impacts of COVID: observations from the frontline

ABSTRACT

P77 Table 1Point prevalence (in the months of Feb & Sept) 2018 – 2022Point prevalence (Feb & Sept) 2018 2019 2020 2021 2022(only Feb 2022) NSCLC 13 12 10 21 7 SCLC 3 5 1 0 3 Mesothelioma 1 3 3 1 0 Stage 1 27% 24% 29% 31% 28% Stage 2 4% 12% 0% 3% 6% Stage 3 14% 24% 06% 16% 17% Stage 4 55% 40% 65% 50% 50% M1a 7(35%) 9(45%) 4(28.5%) 5(22.7%) 2(20%) M1b 3(17.6%) 0 (0%) 2(14.25%) 1(4.5%) 3(30%) M1c 2(11.7%) 1 (5%) 5 (35.7%) 10 (45.45%) 4(40%) Metastasis Brain 2 (11.7%) 1 (5%) 2 (14.2%) 5 (23%) 1 (10%) Adrenal 4 (24%) 2 (10%) 1 (7%) 5 (23%) 1 (10%) Bone 7 (41) 0 (0%) 3 (21%) 8 (36%) 7 (70%) Liver 6 (35%) 3 (15%) 1 (7%) 7 (32%) 5 (50%) Total 12 (71%) 10 (50%) 11 (79%) 16 (73%) 7 (70%) ConclusionThere was a drop in new lung cancer diagnoses and histological confirmation during the pandemic, followed by a trend of increased in numbers and more advanced stage at time of diagnoses in 2022 and statistical significant increase in patients with M1c.While these findings are from a single centre, they highlight a pressing need to prioritise the analysis and publication of national trends. Understanding these trends and their causes – such as delays in presentation or referrals from primary care, and reduced access to diagnostic procedures – will be key to mitigating morbidity and mortality in Lung cancer in the UK.